| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CLINICAL STUDY |
Department of Psychiatry, 1 Department of Endocrinology and Metabolism, and 2 Department of Cardiology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
(Correspondence should be addressed to E M Wekking; Email: ewekking{at}fsw.leidenuniv.nl)
Objective: Hypothyroidism is associated with neurocog.nitive impairment. Sparse data suggest that treatment of hypothyroidism, resulting in a return to euthyroidism, may be associated with only partial recovery of overall neurocognitive functioning. The aim of this study was to assess neurocognitive functioning and well-being in euthyroid patients with primary hypothyroidism on adequate thyroxine (T4) treatment. We also investigated whether serum TSH and thyroid antibodies are determinants of neurocognitive functioning and well-being.
Design: We assessed neurocognitive functioning and well-being in 141 patients with primary hypothyroidism.
Methods: Neurocognitive test results and scores on questionnaires measuring well-being of 141 patients were compared with the reference values for these tests as published and used in Dutch clinical neuropsychological practice. Assessment of neurocognitive functioning included tests for cognitive or psychomotor speed, attention, working memory as well as learning and memory. Well-being was measured with the Symptom Check List-90 total score and the Rand 36-item Health Survey subscales for ‘mental health’ and ‘vitality’.
Results: Patients showed poor performance on various domains of neurocognitive functioning compared with mean standard reference values, especially on a complex attention task and on verbal memory tests. Levels of well-being were significantly lower for patients compared with those of the general population. Neither serum TSH nor thyroid antibodies were determinants of neurocognitive functioning and well-being.
Conclusion: The results of this study suggest that neurocognitive functioning as well as psychological well-being may not be completely restored in patients with hypothyroidism, despite T4 treatment.
This article has been cited by other articles:
|
|
 |
|
  E. H. Schlenker, M. Hora, Y. Liu, R. A. Redetzke, E. Morkin, and A. M. Gerdes Effects of thyroidectomy, T4, and DITPA replacement on brain blood vessel density in adult rats Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1504 - R1509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Cooper Thyroxine Monotherapy After Thyroidectomy: Coming Full Circle JAMA, February 20, 2008; 299(7): 817 - 819. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Slawik, B. Klawitter, E. Meiser, M. Schories, O. Zwermann, K. Borm, M. Peper, B. Lubrich, M. J. Hug, M. Nauck, et al. Thyroid Hormone Replacement for Central Hypothyroidism: A Randomized Controlled Trial Comparing Two Doses of Thyroxine (T4) with a Combination of T4 and Triiodothyronine J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4115 - 4122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Saravanan, T. J. Visser, and C. M. Dayan Psychological Well-Being Correlates with Free Thyroxine But Not Free 3,5,3'-Triiodothyronine Levels in Patients on Thyroid Hormone Replacement J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3389 - 3393. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
